CA2652983C - Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof - Google Patents

Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof Download PDF

Info

Publication number
CA2652983C
CA2652983C CA2652983A CA2652983A CA2652983C CA 2652983 C CA2652983 C CA 2652983C CA 2652983 A CA2652983 A CA 2652983A CA 2652983 A CA2652983 A CA 2652983A CA 2652983 C CA2652983 C CA 2652983C
Authority
CA
Canada
Prior art keywords
proinsulin
nucleic acid
acid molecule
activity
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2652983A
Other languages
English (en)
French (fr)
Other versions
CA2652983A1 (en
Inventor
Enrique J. De La Rosa Cano
Maria Flora De Pablo Davila
Patricia Boya Tremoleda
Silvia Corrochano Sanchez
Pedro De La Villa Polo
Rima Barhoum Tannous
Fatima Bosch Tubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universitat Autonoma de Barcelona UAB
Universidad de Alcala de Henares UAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universitat Autonoma de Barcelona UAB, Universidad de Alcala de Henares UAH filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of CA2652983A1 publication Critical patent/CA2652983A1/en
Application granted granted Critical
Publication of CA2652983C publication Critical patent/CA2652983C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2652983A 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof Expired - Fee Related CA2652983C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200601314 2006-05-22
ES200601314A ES2331342B1 (es) 2006-05-22 2006-05-22 Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
PCT/ES2007/070097 WO2007135220A1 (es) 2006-05-22 2007-05-21 Uso de la proinsulina para la elaboración de una composición farmacéutica neuroprotectora, composición terapéutica que la contiene y sus aplicaciones

Publications (2)

Publication Number Publication Date
CA2652983A1 CA2652983A1 (en) 2007-11-29
CA2652983C true CA2652983C (en) 2016-07-19

Family

ID=38722988

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2652983A Expired - Fee Related CA2652983C (en) 2006-05-22 2007-05-21 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof

Country Status (7)

Country Link
US (1) US20100330042A1 (https=)
EP (1) EP2042189B1 (https=)
JP (1) JP4727748B2 (https=)
AU (1) AU2007253212B2 (https=)
CA (1) CA2652983C (https=)
ES (2) ES2331342B1 (https=)
WO (1) WO2007135220A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021974A1 (en) * 2010-10-05 2011-01-27 Shantha Totada R Retinitis pigmentosa treatment and prophalaxis
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66610A (en) * 1981-08-27 1985-11-29 Lilly Co Eli Human proinsulin pharmaceutical formulations
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5667968A (en) * 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
DE69508605T2 (de) * 1994-07-08 1999-07-22 Trustees Of Dartmouth College, Hanover, N.H. Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
WO2000004171A1 (en) * 1998-07-15 2000-01-27 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor

Also Published As

Publication number Publication date
EP2042189A1 (en) 2009-04-01
ES2331342B1 (es) 2010-10-13
ES2433389T3 (es) 2013-12-10
ES2331342A1 (es) 2009-12-29
AU2007253212B2 (en) 2012-09-27
WO2007135220A1 (es) 2007-11-29
CA2652983A1 (en) 2007-11-29
AU2007253212A1 (en) 2007-11-29
EP2042189A4 (en) 2010-02-17
JP2009537612A (ja) 2009-10-29
EP2042189B1 (en) 2013-06-26
US20100330042A1 (en) 2010-12-30
JP4727748B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
Kobayashi et al. HRG4 (UNC119) mutation found in cone–rod dystrophy causes retinal degeneration in a transgenic model
Petters et al. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa
Pang et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEβ mutation
Bruneau et al. Cardiac expression of the ventricle-specific homeobox gene Irx4 is modulated by Nkx2-5 and dHand
JP6827320B2 (ja) ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法
US6180613B1 (en) AAV-mediated delivery of DNA to cells of the nervous system
US7094948B2 (en) Transgenic animals
JPH10508025A (ja) 眼の遺伝子療法
RU2251838C2 (ru) Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
Jones et al. Retinal expression of γ-crystallins in the mouse
Palmer et al. Expression of Gtf2ird1, the Williams syndrome-associated gene, during mouse development
US11351225B2 (en) Methods for modulating development and function of photoreceptor cells
JPH10500564A (ja) ニューロンプロモーターおよび利用
US20040055023A1 (en) Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
CA2652983C (en) Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
JP2002087983A (ja) 筋萎縮性側索硬化症治療剤
JP2000516212A (ja) ガラニン
Yokoyama et al. Genomic structure and functional characterization of NBPhox (PMX2B), a homeodomain protein specific to catecholaminergic cells that is involved in second messenger-mediated transcriptional activation
CN113956345B (zh) Angpt4蛋白及其编码基因在调控心脏损伤后的修复与再生能力中的应用
WO1998015628A1 (fr) Nouveau gene de semaphorine: la semaphorine w
WO2005023311A2 (en) Novel targets for the treatment of retina diseases
Wei Neural stem cell-based GDNF and CNTF for the treatment of retinal degeneration in a mouse model of CLN7 disease
Ramon et al. Molecular biology of retinitis pigmentosa: therapeutic implications
Douglas Glial Cell Line-derived Neurotrophic Factor Rescues Photoreceptors from Death in Mouse Models of Retinitis Pigmentosa
RAKÓCZY et al. Eye diseases

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180522